ArticleClinical nephrology2025
Metabolic health in the Slovenian national cohort of kidney transplant patients.
Article in Clinical nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic health refers to the proper functioning and balance of metabolic processes in our bodies. The metabolism of carbohydrates, lipids, and proteins has a direct impact on the cardiovascular system. Recent advances in pharmacotherapy have introduced several drugs into clinical practice that can improve cardiometabolic health. MATERIALS AND
methodsBetween September 2023 and March 2024, we systematically collected cardiometabolic data from 800 kidney transplant patients (KTPs) during their routine outpatient visits. These included clinical data - office blood pressure, body weight and height, body mass index (BMI), and waist circumference (WC) - and laboratory data such as high-sensitivity C-reactive protein (hs-CRP), lipid profile, lipoprotein(a) (Lp(a)), glycated hemoglobin (HbA1c), serum urate, serum albumin, and proteinuria from spot urine samples. Patients who required treatment adjustment were selected.
resultsDeviations from the desired values of individual components of the metabolic syndrome (blood pressure, WC, triglycerides, high-density lipoprotein cholesterol, and fasting glucose) were observed in 23 - 61.5% of patients. Elevated hs-CRP levels (5 - 10 mg/L), a known cardiovascular risk factor, were observed in 13.5% of patients. Lp(a) levels exceeded the upper normal limit (> 500 mg/L) in 17% of patients. Only a small proportion of patients with moderate to advanced kidney disease - 13% and 23.6%, respectively - had low-density lipoprotein cholesterol levels within the reference range.
conclusionsBetween 23% and 61.5% of patients failed to meet target values for individual components of metabolic health. The largest deviation (61.5%) was observed in WC among women. WC and waist-to-height ratio are two simple and reliable parameters for assessing metabolic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.